New York, NY, January 21, 2017 --(PR.com
)-- The Knowledge Group/The Knowledge Congress Live Webcast Series, the leading producer of regulatory focused webcasts, has announced today that Brian V. Slater, Partner, Kramer Levin Naftalis & Frankel LLP will speak at the Knowledge Group’s webcast entitled: “Resolving Patent Dispute Under BPCIA: Latest Developments and Strategies in 2017 Live Webcast.” This event is scheduled for February 14, 2017 from 3:00pm – 5:00pm (ET).
For further details, please visit: https://theknowledgegroup.org/event-homepage/?event_id=2111
About Brian V. Slater
Brian V. Slater, is Chair of the Life Sciences practice at Kramer Levin Naftalis & Frankel LLP. Mr. Slater has over 25 years of patent litigation experience, including serving as first chair for clients including Forward Pharma, Gilead, Merck and Sanofi. He has litigated biotechnology cases relating to fusion proteins, diagnostic kits and labeled nucleotides, and he counsels biologic/biosimilar clients on navigating the BPCIA litigation pathway. He also has litigated numerous cases under the Hatch-Waxman Act, most recently helping Merck to win a judgment of patent infringement against Xellia Pharmaceuticals relating to a patent covering the life-saving, antifungal drug, Cancidas®.
Clients describe Mr. Slater as “a great decision maker” (IAM Patent 1000 2012) who is “admired for his strategic nous and calm demeanor in pressurized litigation scenarios” (IAM Patent 1000 2013) and is “brilliant on biosimilars.” (IAM Patent 1000 2014).
About Kramer Levin Naftalis & Frankel LLP
Kramer Levin Naftalis & Frankel LLP is a premier, full-service law firm with offices in New York, Silicon Valley and Paris. Firm lawyers are leading practitioners in their respective fields. The firm represents public and private companies – ranging from Global 1000 to middle-market and emerging growth companies – across a broad range of industries, as well as funds, institutions and individuals. For more information, please visit www.kramerlevin.com.
Since its enactment as a component of the Patient Protection and Affordable Care Act on March 23, 2010, the Biologics Price Competition and Innovation Act (collectively known as BPCIA) has continually created an abbreviated approval pathway for producers of biological products. Primarily, the act caters for products which are “biosimilar” to or “interchangeable” with FDA-licensed biological products.
One of the most significant cases on BPCIA was the recently culminated Amgen-Sandoz Fight, which created a buzz on the industry and questioned how mandatory the “Patent Dance” is.
In a two-hour live Webcast, a panel of thought leaders and practitioners assembled by The Knowledge Group will discuss the significant and latest issues surrounding the BPCIA. Aside from the updates and recent developments, they will further discuss 2017 strategies which will be helpful for both innovators and biosimilar applicants.
Key issues that will be covered in this course are:
· Supreme Court to hear the Amgen-Sandoz Fight
- Case Background
- The Neupogen® // Zarxio™ Biosimilar Dispute
- Questions the Supreme Court will address:
-- Is Patent Dance mandatory?
-- Is 180-day notice of commercial marketing mandatory? When must it be given?
- Implications of possible Supreme Court decision outcomes
· What open questions does the Supreme Court case not address?
· 2017 BPCIA Strategies Outlook
About The Knowledge Group /The Knowledge Congress Live Webcast Series
The Knowledge Group was established with the mission to produce unbiased, objective, and educational live webinars that examine industry trends and regulatory changes from a variety of different perspectives. The goal is to deliver a unique multilevel analysis of an important issue affecting business in a highly focused format. To contact or register for an event, please visit: http://theknowledgegroup.org/